Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2009-08-24FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA approved a supplemental application for chlorpromazine hydrochloride from Upsher-Smith Laboratories, a generic antipsychotic.
-
FDA approval · 2009-08-24FDA Approved: RISPERIDONE — Supplemental Application (Amici Pharma, Inc.)
FDA approved a supplemental application for risperidone by Amici Pharma, Inc., signaling a labeling update or additional indication for the …
-
CLINICAL_TRIALS research · 2009-08-19Clinical Trial Update: Non Interventional Study In Bipolar Disorder And Schizophrenia With Zeldox
A completed non-interventional study in bipolar disorder and schizophrenia assessing Zeldox (ziprasidone) by Pfizer/Mylan Viatris; results p…
-
FDA approval · 2009-08-18FDA Approved: PERPHENAZINE — Supplemental Application (Endo USA, Inc.)
FDA approved a supplemental application for PERPHENAZINE submitted by Endo USA, Inc., resulting in an updated labeling for the product.
-
FDA approval · 2009-08-18FDA Approved: CHLORPROMAZINE HYDROCHLORIDE — Supplemental Application (Upsher-Smith Laboratories, LLC)
The FDA granted a supplemental approval for chlorpromazine hydrochloride from Upsher-Smith Laboratories, LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2009-08-13FDA Approved: SAPHRIS — Original Application (Allergan, Inc.)
The FDA approved SAPHRIS (asenapine maleate) from Allergan in an original application for the treatment of schizophrenia and for the acute t…
-
CLINICAL_TRIALS trial_result · 2009-08-12Clinical Trial Update: A Placebo-Controlled Trial of Modafinil (Provigil) Added to Clozapine in Patients With Schizophrenia [Phase 4]
A Phase 4, placebo-controlled trial evaluated adding modafinil to clozapine in patients with schizophrenia, and the study status shows as co…
-
CLINICAL_TRIALS research · 2009-08-12Clinical Trial Update: Disturbances of Kynurenine Pathway of Trytophan Metabolism in Schizophrenia: A Quantitative Reverse Transcription Polymerase Chain Reaction (RT-PCR) Study
A completed clinical trial examining disturbances in the kynurenine pathway of tryptophan metabolism in schizophrenia, using quantitative RT…
-
CLINICAL_TRIALS trial_result · 2009-08-07Clinical Trial Update: Changes in Hyperprolactinemia Secondary to Antipsychotics After Switching to Quetiapine
A completed clinical trial evaluated prolactin changes in patients with antipsychotic-induced hyperprolactinemia after switching to quetiapi…
-
CLINICAL_TRIALS trial_result · 2009-08-07Clinical Trial Update: Safety, PK and PD Study in Healthy Male Japanese Subjects [Phase 1]
Phase 1 safety, pharmacokinetic (PK) and pharmacodynamic (PD) study in healthy male Japanese subjects has completed; Wyeth (now Pfizer) spon…
-
CLINICAL_TRIALS trial_result · 2009-08-06Clinical Trial Update: The Effects of Varenicline on Cognitive Function in Patients With Schizophrenia [Phase 3]
A Phase 3 study assessed varenicline for improving cognitive function in patients with schizophrenia; the trial has completed.
-
CLINICAL_TRIALS research · 2009-08-06Clinical Trial Update: The New Strategy for Pharmacological Treatment in People With Schizophrenia [Phase 4]
A Phase 4 clinical trial update describing a new pharmacological strategy for treating schizophrenia. The current status of the trial is UNK…
-
CLINICAL_TRIALS trial_result · 2009-08-04Clinical Trial Update: Study Evaluating Multiple Ascending Dose in Schizophrenia Patients [Phase 1]
Phase 1 multiple ascending dose study in schizophrenia patients was terminated; sponsor Wyeth is now part of Pfizer.
-
CLINICAL_TRIALS trial_result · 2009-08-04Clinical Trial Update: Efficacy Study of Early Onset of Antipsychotic Drug Action in Schizophrenia [Phase 4]
Phase 4 clinical trial update on early onset antipsychotic drug action in schizophrenia and related disorders; results have been posted.
-
CLINICAL_TRIALS trial_result · 2009-08-03Clinical Trial Update: Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia [Phase 4]
This Phase 4 trial compares the efficacy and safety of risperidone oral solution with clonazepam versus haloperidol given intramuscularly fo…
-
CLINICAL_TRIALS trial_result · 2009-08-03Clinical Trial Update: An Observational Study of Olanzapine Coated and Orodispersible Tablets Effectiveness in Schizophrenic and Bipolar Outpatients.
Observational study evaluating the effectiveness of olanzapine-coated and orodispersible tablets in outpatients with schizophrenia or bipola…
-
FDA approval · 2009-07-31FDA Approved: INVEGA SUSTENNA — Original Application (Janssen Pharmaceuticals, Inc.)
This FDA entry records the original NDA approval of Invega Sustenna (paliperidone palmitate) by Janssen Pharmaceuticals for the treatment of…
-
FDA approval · 2009-07-31FDA Approved: INVEGA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for INVEGA (paliperidone) submitted by Janssen Pharmaceuticals, Inc.
-
CLINICAL_TRIALS trial_result · 2009-07-29Clinical Trial Update: Creatine Treatment in Psychiatric Disorders [Phase 3]
This Phase 3 clinical trial update reports the completion of a study evaluating creatine as a treatment for schizophrenia.
-
CLINICAL_TRIALS withdrawal · 2009-07-28Clinical Trial Update: Lamictal TM, Haloperidol Decanoate in Schizophrenia [Phase 4]
Phase 4 trial of Lamictal and haloperidol decanoate for schizophrenia has been terminated.
-
CLINICAL_TRIALS trial_result · 2009-07-23Clinical Trial Update: Safety Study of Olanzapine and a Comparator in Patients With Schizophrenia and Schizoaffective Disorder [Phase 4]
A Phase 4 safety study comparing olanzapine to a comparator in schizophrenia and schizoaffective disorder has completed and results have bee…
-
FDA approval · 2009-07-22FDA Approved: FLUPHENAZINE DECANOATE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved Fresenius Kabi USA's supplemental application for fluphenazine decanoate, a long-acting injectable antipsychotic, indicatin…
-
FDA approval · 2009-07-21FDA Approved: FLUPHENAZINE HYDROCHLORIDE — Supplemental Application (Fresenius Kabi USA, LLC)
The FDA approved a supplemental application for Fluphenazine hydrochloride from Fresenius Kabi USA, LLC, confirming/expanding its generic pr…
-
CLINICAL_TRIALS trial_result · 2009-07-21Clinical Trial Update: Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder [Phase 2]
Phase 2 study evaluating the safety and tolerability of BL-1020 in hospitalized patients with schizophrenia or schizoaffective disorder has …
-
FDA approval · 2009-07-19FDA Approved: RISPERDAL M-TAB — Supplemental Application (Janssen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Risperdal M-TAB (risperidone) from Janssen Pharmaceuticals. The notice lists the submission stat…